CARMEN MAGISTRO: Open Payments
NPI 1841258563 · BELLEVUE, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,181 in 63 payments from 19 companies in 2025. Trend: 2023 $1,412 · 2024 $1,879 · 2025 $1,181
Food & beverage: $1,181
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 9 | $226 |
| Novo Nordisk Inc | 11 | $197 |
| Lilly USA, LLC | 14 | $170 |
| PFIZER INC. | 4 | $85 |
| Astellas Pharma US Inc | 2 | $71 |
| ABBVIE INC. | 3 | $70 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $52 |
| Edwards Lifesciences Corporation | 2 | $46 |
| Janssen Pharmaceuticals, Inc | 2 | $40 |
| Acella Pharmaceuticals, LLC | 2 | $37 |
Products named: MOUNJARO, Wegovy, Veozah, PAXLOVID, Kerendia, SPRAVATO, QULIPTA, NP Thyroid 60.
Industry payments across NE — which companies pay providers there.
